Risks to shipments, procurement, order intake and deliveries due to COVID-19
First written in FY2020-Q2. 6 of 15 entries say "Restated". Latest entry: FY2024-Q2.
The whole theme swung hardest in 2025: 5 of 16 companies on the "Worse" side.
19 other companies' latest entry also says "Restated".
- FY2024-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It is reconfirmed that there have been no new or material changes in existing business and other risks, including COVID-19. - FY2024-Q1RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It is stated that there have been no new or material changes in business and other risks, including COVID-19. - FY2023-Q3RestatedAnnual report
「There have been no material changes in the impact of COVID-19 on accounting estimates described in the notes to the securities report for the previous consolidated fiscal year.」
It is reconfirmed that there have been no material changes from the previous fiscal year in the impact of COVID-19 on accounting estimates. - FY2023-Q2RestatedAnnual report
「There have been no material changes in the impact of COVID-19 on accounting estimates described in the notes to the securities report for the previous consolidated fiscal year.」
It is stated that there have been no material changes from the previous fiscal year in the impact of COVID-19 on accounting estimates. - FY2023-Q1RestatedAnnual report
「There have been no material changes in the impact of COVID-19 on accounting estimates described in the notes to the securities report for the previous consolidated fiscal year.」
It is stated that there have been no material changes from the previous fiscal year in the impact of COVID-19 on accounting estimates. - FY2022RestatedAnnual report
「In response to these risks, we prohibited domestic and overseas business travel, asked employees to refrain from attending meetings involving large numbers of unspecified participants, such as seminars, exhibitions and social gatherings, restricted travel between sites, asked customers to refrain from visiting our offices, and reminded employees to take precautions against infection in their daily lives. These measures minimized the impact of the spread of infection on production lines. Financially, we reviewed our investment plans and entered into a commitment line to prepare for any funding contingencies.」
The risks to shipments, order intake, deliveries and procurement associated with COVID-19 continue to be recognized, and measures involving infection prevention, a review of investment plans and a commitment line are reiterated. - FY2022-Q2MitigatedAnnual report
「Although conditions remain uncertain due to the renewed spread of COVID-19 and other factors, sales to each industry have been increasing steadily, and we believe the impact on performance is minor.」
Although uncertainty from the renewed spread of COVID-19 remains, the impact on performance is considered minor due to increased sales across industries. - FY2022-Q1MaterialisedAnnual report
「The difficulty of procuring materials such as electronic components has also begun to affect manufacturing and delivery schedules, but its impact on the consolidated earnings forecast for the fiscal year ending September 2022 is currently minor.」
In addition to the renewed spread of COVID-19 and the Omicron variant, difficulties in procuring materials such as electronic components have begun to affect manufacturing and delivery schedules. Meanwhile, the impact on the full-year earnings forecast is currently considered minor. - FY2021MitigatedAnnual report
「Although some effects of COVID-19 remain, sales, particularly of medical and biotechnology equipment and industrial equipment, are growing steadily. Accordingly, the Group has made accounting estimates concerning impairment of fixed assets and the recoverability of deferred tax assets based on the assumption that the impact of COVID-19 on the Group is limited.」
Although some effects of COVID-19 remain, sales, particularly of medical and biotechnology equipment and industrial equipment, are growing, and the accounting assumption is that the impact is limited. - FY2021-Q3MitigatedAnnual report
「Regarding the impact of COVID-19 on consolidated performance, some effects remain, but sales have exceeded pre-pandemic levels due to the recovery and expansion of the semiconductor market and steady performance of products for specimen-testing equipment, including PCR equipment.」
Some effects of COVID-19 remain, but sales exceeded pre-pandemic levels on the recovery and expansion of the semiconductor market and strong demand for specimen-testing products, including PCR products. The impact on performance has eased further. Meanwhile, concerns about the renewed spread of infections caused by variant viruses remain. - FY2021-Q2MitigatedAnnual report
「Regarding the impact of COVID-19 on consolidated performance, sales to industries including medical and biotechnology equipment and industrial equipment have been increasing and recovering steadily, but concerns about the renewed spread of infections in Japan and overseas remain.」
Sales of medical and biotechnology equipment, industrial equipment and other products increased, and consolidated performance is recovering steadily, while concerns about the renewed spread of infections in Japan and overseas remain. - FY2021-Q1The effects persisted amid renewed infections, while overall conditions gradually recoveredAnnual report
「Restrictions on the production and sales activities of customers, including companies, universities and research institutions, have continued in part due to travel restrictions and other measures resulting from the renewed spread of COVID-19 in Japan and overseas. Some industries continue to be affected by lower sales from their peaks, but overall conditions are gradually recovering.」
Restrictions on customer activities and lower sales in some industries due to the renewed spread of COVID-19 remain, while overall conditions are showing a gradual recovery trend. - FY2020MaterialisedAnnual report
「The Group’s business activities and performance for the fiscal year ended September 2020 were affected by delays in product deliveries and fewer order opportunities, among other effects, as economic activity stagnated worldwide amid the spread of COVID-19 and concerns that the stagnation would be prolonged.」
The effects of delays in product deliveries and fewer order opportunities were confirmed as affecting annual performance. For accounting purposes, the assumption was made that the effects would continue through the first half of the fiscal year ending September 2021 and recovery would occur in the second half. - FY2020-Q3MaterialisedAnnual report
「The Group’s business activities and performance during the nine-month period ended 30 September 2020 were affected by delays in product deliveries and fewer order opportunities, among other effects, as economic activity stagnated worldwide amid the spread of COVID-19 and concerns that the stagnation would be prolonged.」
The delays in product deliveries and decline in order opportunities from COVID-19, previously described as concerns, actually occurred and were recognized as affecting business activities and performance. - FY2020-Q2First statedAnnual report
「The global spread of COVID-19 has raised concerns about product shipments due to reduced air services, procurement of components due to supply chain instability, fewer opportunities to receive orders from domestic and overseas customers due to restrictions on business travel, and delays in product deliveries. If the effects of COVID-19 continue for an extended period, they may affect the operating performance and financial condition of the Group.」
Specific concerns regarding COVID-19, including reduced air services, component procurement, order opportunities affected by travel restrictions and delays in product deliveries, have been added.